Company intelligence / Profile preview
Eris Biotech
American Fork, Utah, United Stateserisbio.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Eris Biotech is developing small molecule hypoxia-activated prodrugs that only become active within the low oxygen environment characteristic of most solid tumors. Their lead program targets mesothelioma by blocking tumor-stroma communication and engaging the immune system. The approach aims to maximize anti-tumor efficacy while minimizing systemic toxicity. No clinical results have been reported as programs are pre-clinical.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeHypoxia-activated prodrug (HAP)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Eris Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eris Biotech.